From post-translational modification to drug discovery

The Tate lab develops novel chemical biology approaches to enable drug discovery against post-translational modification (PTM) pathways and intractable drug targets, including chemical proteomic target identification, screening technologies, and chemical probe discovery for protein-protein interactions and enzymes modulating PTMs. Recent highlights include the first cell-active activity-based probes (ABPs) for deubiquitinases (DUBs), new tools for analysis and discovery of pathogenic secreted protease activities, and the first comprehensive maps of specific classes of protein lipidation PTM through chemical proteomics. We are also interested in new modalities including antibody-PROTAC conjugates, and translation of drug candidates.